期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

LCZ696治疗心力衰竭的研究进展 被引量：2

在线阅读 下载PDF
导出
摘要 心力衰竭是各种心血管疾病的严重和终末阶段,发病率和致死率高,预后不良,是目前严重威胁人类健康的疾病之一。心力衰竭是由于各种病因引起心室充盈和射血功能受损,最后导致心室泵血功能低下的疾病。我国部分地区42家医院对10 714例心力衰竭住院患者进行回顾性调查发现,心力衰竭的病因中,冠心病所占比例逐年上升,居各种病因之首,其次为高血压,风湿性心脏瓣膜病所占比例则下降。
作者 徐梦林 黄晶
机构地区 重庆医科大学附属第二医院心内科
出处 《现代医药卫生》 2015年第8期1176-1178,共3页 Journal of Modern Medicine & Health
关键词 心力衰竭 血管紧张素Ⅱ1型受体拮抗剂 脑啡肽酶 LCZ696 综述
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献25

  • 1程康安,吴宁.中国部分地区1980、1990、2000年慢性心力衰竭住院病例回顾性调查[J].中华心血管病杂志,2002,30(8):450-454. 被引量：365
  • 2McMurray 11 ,Adamopoulos S, Anker SD ,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association(HFA) of the ESC[J]. Eur 1 Heart Fail, 2012,14(8) :803-869.
  • 3Schroten NF ,Gaillard CA, van Veldhuisen Dl ,et al. New roles for renin and prorenin in heart failure and cardiorenal crosstalk[J]. Heart Fail Rev, 2012,17(2): 191-201.
  • 4von Lueder TG,Krum H. RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials[J]. Cardiovasc Drugs Ther ,2013 ,27 (2) : 171-179.
  • 5Cohn IN, Tognoni G, Valsartan Heart Failure Trial Investigators. A ran?domized trial of the angiotensin-receptor blocker valsartan in chronic heart failure[J]. N Engl 1 Med,2001 ,345 (23) : 1667-1675.
  • 6Voors AA ,Dorhout B, van der Meer P. The potential role of valsartan+ AHU377 (LCZ696) in the treatment of heart failure[J]. Expert Opin In?vestig Drugs ,2013 ,22(8) : 1041-1047.
  • 7McMurray 11 ,Ostergren 1, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM?Added trial[J]. Lancet ,2003 ,362(9386) : 767-771.
  • 8Van de Wal RM ,van Veldhuisen DJ , van Gilst WH, et al. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense[J]. Eur Heart 1,2005,26(22) :2361-2367.
  • 9Levin ER,Gardner DG,Samson WK. Natriuretic peptides[J]. N Engl 1 Med, 1998,339:321-328.
  • 10Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders[J]. Drugs, 2003 ,63 (20) : 2185-2202.

二级参考文献7

  • 1Kalon KL,Joan LP, William BK. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol, 1993,22 (Suppl A):6A-13A.
  • 2Hung YT, Cheug NT, Ip S. Epidemiology of heart failure in Hong Kong,1997. Hong Kong Med J, 2000,6:159-162.
  • 3Packer M, Coats AJS, Fowler MB, et al. For the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effects of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001, 344:1651-1658.
  • 4Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J, 2001, 22: 1527-1561.
  • 5Hunt HA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the international society for heart and lung transplantation. Circulation, 2001, 104:2996-3007.
  • 6上海市心力衰竭调查协作组,范维琥,张平宽,李勇.上海市稳定性心力衰竭患者药物治疗现状调查[J].中华心血管病杂志,2001,29(11):644-648. 被引量：37
  • 7慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量：2414

共引文献363

同被引文献13

引证文献2

二级引证文献12

现代医药卫生
2015年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部